These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 34814708)
1. Selective CDK9 degradation using a proteolysis-targeting chimera (PROTAC) strategy. Mallareddy JR; Singh S; Boghean L; Natarajan A Future Med Chem; 2022 Jan; 14(3):131-134. PubMed ID: 34814708 [No Abstract] [Full Text] [Related]
2. Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. Sonawane YA; Taylor MA; Napoleon JV; Rana S; Contreras JI; Natarajan A J Med Chem; 2016 Oct; 59(19):8667-8684. PubMed ID: 27171036 [TBL] [Abstract][Full Text] [Related]
3. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax. King HM; Rana S; Kubica SP; Mallareddy JR; Kizhake S; Ezell EL; Zahid M; Naldrett MJ; Alvarez S; Law HC; Woods NT; Natarajan A Bioorg Med Chem Lett; 2021 Jul; 43():128061. PubMed ID: 33895280 [TBL] [Abstract][Full Text] [Related]
4. Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity. Bian J; Ren J; Li Y; Wang J; Xu X; Feng Y; Tang H; Wang Y; Li Z Bioorg Chem; 2018 Dec; 81():373-381. PubMed ID: 30196207 [TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor. Lim SL; Xu L; Han BC; Shyamsunder P; Chng WJ; Koeffler HP PLoS One; 2020; 15(6):e0232068. PubMed ID: 32559187 [TBL] [Abstract][Full Text] [Related]
6. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion. Qiu X; Li Y; Yu B; Ren J; Huang H; Wang M; Ding H; Li Z; Wang J; Bian J Eur J Med Chem; 2021 Feb; 211():113091. PubMed ID: 33338869 [TBL] [Abstract][Full Text] [Related]
7. Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. Wu T; Qin Z; Tian Y; Wang J; Xu C; Li Z; Bian J J Med Chem; 2020 Nov; 63(22):13228-13257. PubMed ID: 32866383 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Olson CM; Jiang B; Erb MA; Liang Y; Doctor ZM; Zhang Z; Zhang T; Kwiatkowski N; Boukhali M; Green JL; Haas W; Nomanbhoy T; Fischer ES; Young RA; Bradner JE; Winter GE; Gray NS Nat Chem Biol; 2018 Feb; 14(2):163-170. PubMed ID: 29251720 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of Wee1 kinase degraders. Zhu S; Liu J; Xiao D; Wang P; Ma J; Hu X; Fu J; Zhou Y; Li J; Lu W Eur J Med Chem; 2022 Dec; 243():114786. PubMed ID: 36170799 [TBL] [Abstract][Full Text] [Related]
10. Uncovering potential CDK9 inhibitors from natural compound databases through docking-based virtual screening and MD simulations. Singh P; Kumar V; Jung TS; Lee JS; Lee KW; Hong JC J Mol Model; 2024 Jul; 30(8):267. PubMed ID: 39012568 [TBL] [Abstract][Full Text] [Related]
11. Discovery of novel CDK inhibitors via scaffold hopping from CAN508. Jing L; Tang Y; Xiao Z Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093 [TBL] [Abstract][Full Text] [Related]
12. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy. Alsfouk A J Enzyme Inhib Med Chem; 2021 Dec; 36(1):693-706. PubMed ID: 33632038 [TBL] [Abstract][Full Text] [Related]
13. Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement. Barlaam B; De Savi C; Dishington A; Drew L; Ferguson AD; Ferguson D; Gu C; Hande S; Hassall L; Hawkins J; Hird AW; Holmes J; Lamb ML; Lister AS; McGuire TM; Moore JE; O'Connell N; Patel A; Pike KG; Sarkar U; Shao W; Stead D; Varnes JG; Vasbinder MM; Wang L; Wu L; Xue L; Yang B; Yao T J Med Chem; 2021 Oct; 64(20):15189-15213. PubMed ID: 34647738 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9. Itkonen HM; Poulose N; Steele RE; Martin SES; Levine ZG; Duveau DY; Carelli R; Singh R; Urbanucci A; Loda M; Thomas CJ; Mills IG; Walker S Mol Cancer Res; 2020 Oct; 18(10):1512-1521. PubMed ID: 32611550 [TBL] [Abstract][Full Text] [Related]
15. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer. Wei D; Wang H; Zeng Q; Wang W; Hao B; Feng X; Wang P; Song N; Kan W; Huang G; Zhou X; Tan M; Zhou Y; Huang R; Li J; Chen XH J Med Chem; 2021 Oct; 64(19):14822-14847. PubMed ID: 34538051 [TBL] [Abstract][Full Text] [Related]